Innate pharma to participate in the H.C. Wainwright 28th annual global investment conference
Innate Pharma announces conference call and webcast
Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares
Innate Pharma Announces Proposed Offering of Ordinary Shares
Innate Pharma to advance Lacutamab towards phase 3 following partnership with Sobi and appoints new chief medical officer
Innate Pharma enters strategic partnership with Sobi to license lacutamab in T-cell lymphoma
Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference
Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)
Outcome of Innate Pharma’s 2026 Annual General Meeting
Innate Pharma to participate in the Jefferies Global Healthcare Conference
